Carreras-Puigvert & Spjuth (2024)
Artificial intelligence for high content imaging in drug discovery. Current Opinion in Structural Biology.
View DOIHow generalist AI and foundation models are changing image analysis for cell-based assays โ and what UK labs should know before choosing a platform.
For years, analysing fluorescence microscope images meant drawing regions by hand, tuning thresholds in ImageJ, or paying for specialist high-content software. The new generation of AI โ and the path toward artificial general intelligence โ flips that workflow. A model trained on millions of cell images can segment a new cell type, classify a phenotype, or flag a rare event without a human writing a custom algorithm for every assay.
This matters for UK cell-biology labs in three practical ways:
The key is matching the right microscope, the right software and the right validation framework. Hardware without a clean data-export path is as limiting as software without ground-truth data.
Despite the marketing noise, today's AI image-analysis tools are narrow specialists at the task level, even when they feel generalist. In a typical cell-based assay workflow they perform five core jobs:
Tools such as CellPose and CellProfiler handle the first two tasks for free. QuPath dominates multiplex tissue analysis. Commercial suites add the last three, often with plate-scale dashboards and regulatory-ready audit trails.
| Platform | Best for | Deployment | Price signal |
|---|---|---|---|
| CellProfiler | Batch image analysis, morphological features | Local or HPC | Open source |
| CellPose | Generalist cell/nucleus segmentation | Python, Fiji plugin, cloud | Open source / commercial CellPose.io |
| QuPath | Multiplex IHC/IF on tissue sections | Local workstation | Open source |
| Aivia | 3D segmentation, deep-learning workflows | Local or network | Perpetual or subscription licence |
| Nikon NIS.ai | Nikon microscope-integrated denoising/segmentation | On-instrument | Part of Nikon ecosystem |
| ZEISS arivis | Large 3D datasets, correlative workflows | On-premise or cloud | Enterprise licence |
| Thermo Celleste | EVOS and CellInsight image analysis | Local | Bundled or standalone |
| Revvity Signals Image Artist | High-content screening, plate-level statistics | Enterprise server | Enterprise licence |
No single tool wins every assay. A UK academic group running Cell Painting on an EVOS M5000 will usually start with CellProfiler + CellPose, then graduate to a commercial dashboard if the assay moves toward screening. A pharma lab with a CellInsight CX7 will typically use Celleste or Revvity from day one to keep validation simple.
The 2025โ2026 wave of "agentic" systems adds reasoning on top of segmentation. These agents can decide which z-plane to acquire, re-focus a drifting well, or call a human when image quality degrades. Examples include Agent-Lens for smart microscopy and open projects such as Agentic-J for biological image analysis. They are not yet plug-and-play for regulated work, but they are narrowing the gap between imaging hardware and autonomous experimental decision-making.
For UK labs, the near-term value is simpler: an AI agent can pre-screen a 96-well plate, discard unusable fields, and queue only the high-quality images for downstream analysis. That saves storage, compute and human time.
AI image analysis is only as good as the images it receives. The ideal fluorescence microscope for an AI-driven assay has:
Among systems we review on Plankton & Zoom, the EVOS M5000, EVOS M7000 and CellInsight CX7 fit these requirements at different scales. The M5000 and M7000 are excellent for small-to-medium batch assays where images are exported into CellProfiler or CellPose. The CellInsight CX7 is purpose-built for plate-scale high-content screening with integrated analysis.
Foundation models trained on public cell-image collections can fail on your cell line, your stain and your microscope. The standard fix is transfer learning on a small, expert-annotated ground-truth set. For GLP/GMP work, that ground truth needs documented provenance, inter-operator agreement and version-locked software.
Practical validation checklist for UK labs:
Open repositories such as the BioImage Model Zoo make it easier to share and reproduce models, but they do not remove the need for local validation.
Artificial intelligence for high content imaging in drug discovery. Current Opinion in Structural Biology.
View DOIA Decade in a Systematic Review: The Evolution and Impact of Cell Painting. bioRxiv.
View DOICell Painting: a decade of discovery and innovation in cellular imaging. Nature Methods 21:1817โ1828.
View DOIProgress and new challenges in image-based profiling. arXiv.
View DOIEmpowering Biomedical Research with Foundation Models in Computational Microscopy. Advanced Intelligent Systems.
View DOIFrom Pixels to Information: Artificial Intelligence in Fluorescence Microscopy. Advanced Photonics Research.
View DOIAGI image analysis uses generalist AI systems and foundation models to interpret microscopy images without hand-tuned rules for every assay. For cell-based assays it can segment cells, classify phenotypes, track lineages and flag outliers in fluorescence, brightfield and label-free images.
Open-source options include CellProfiler, CellPose and QuPath. Commercial platforms include Aivia, Nikon NIS.ai, ZEISS arivis, Thermo Fisher Celleste and Revvity Signals Image Artist. Cloud tools such as BioImage Model Zoo and Imjoy are also widely used in UK academic labs.
Not fully today. AGI and deep-learning models dramatically reduce manual segmentation and feature extraction in high-content screening, but GLP/GMP studies still need validated pipelines, ground-truth annotations and documented SOPs. Human oversight remains essential for assay sign-off.
Automated inverted fluorescence microscopes with consistent illumination and motorised stages work best. In the Thermo Fisher ecosystem, the EVOS M5000 and EVOS M7000 export TIFF images that feed CellProfiler, CellPose and Celleste. The CellInsight CX7 and CX5 high-content systems are built for plate-scale AI analysis.
Choose on-premise or private-cloud deployment for sensitive patient, clinical or proprietary compound data. Public cloud is acceptable for published datasets and open-source foundation models, but confirm your institutional DPIA and data-processing agreement are in place.